Journal article
Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.
Abstract
SOURCE CITATION: Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. 32843476.
Authors
Hao Q; Guyatt G
Journal
Annals of Internal Medicine, Vol. 174, No. 1,
Publisher
American College of Physicians
Publication Date
January 2021
DOI
10.7326/acpj202101190-011
ISSN
1056-8751